Personal information

Websites & social links

Researchgate

Other IDs

ResearcherID: D-3389-2017

Activities

Collapse all

Works (30)

Data from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.c.7623351
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193748
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193745
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Data Table 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193742
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 1 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193739
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 2 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193736
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 3 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193733
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 4 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193730
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 5 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193727
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 6 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193724
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Supplementary Figure 7 from Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

2025-01-13 | Preprint
DOI: 10.1158/2159-8290.28193721
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers

Cancer Discovery
2025-01-13 | Journal article
DOI: 10.1158/2159-8290.CD-24-0306
Contributors: Birgit Wilding; Lydia Woelflingseder; Anke Baum; Krzysztof Chylinski; Gintautas Vainorius; Neil Gibson; Irene C. Waizenegger; Daniel Gerlach; Martin Augsten; Fiona Spreitzer et al.
Source: check_circle
Crossref

HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies

Journal of Medicinal Chemistry
2023-04-27 | Journal article
DOI: 10.1021/acs.jmedchem.3c00156
Part of ISSN: 0022-2623
Part of ISSN: 1520-4804
Contributors: A. Elisa Pasqua; Swee Y. Sharp; Nicola Chessum; Angela Hayes; Loredana Pellegrino; Michael J. Tucker; Asadh Miah; Birgit Wilding; Lindsay E. Evans; Carl S. Rye et al.
Source: Self-asserted source
Birgit Wilding

Chemoenzymatic one-pot reaction from carboxylic acid to nitrile via oxime

Catalysis Science & Technology
2022 | Journal article
DOI: 10.1039/D1CY01694F
Contributors: Melissa Horvat; Victoria Weilch; Robert Rädisch; Sebastian Hecko; Astrid Schiefer; Florian Rudroff; Birgit Wilding; Norbert Klempier; Miroslav Pátek; Ludmila Martínková et al.
Source: check_circle
Crossref

Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling

Nature Cancer
2022-07 | Journal article
DOI: 10.1038/s43018-022-00412-y
Part of ISSN: 2662-1347
Contributors: Birgit Wilding
Source: Self-asserted source
Birgit Wilding
grade
Preferred source (of 2)‎

Investigating the phosphinic acid tripeptide mimetic DG013A as a tool compound inhibitor of the M1-aminopeptidase ERAP1

Bioorganic & Medicinal Chemistry Letters
2021-06 | Journal article
DOI: 10.1016/j.bmcl.2021.128050
Contributors: Birgit Wilding; A. Elisa Pasqua; Nicola E. A. Chessum; Olivier A. Pierrat; Tamas Hahner; Kathy Tomlin; Erald Shehu; Rosemary Burke; G. Meirion Richards; Bradleigh Whitton et al.
Source: check_circle
Crossref

Privileged Structures and Polypharmacology within and between Protein Families

ACS Medicinal Chemistry Letters
2018-11 | Journal article
DOI: 10.1021/acsmedchemlett.8b00364
Part of ISSN: 1948-5875
Contributors: Joshua Meyers; Nicola E. A. Chessum; Salyha Ali; N. Yi Mok; Birgit Wilding; A. Elisa Pasqua; Martin Rowlands; Michael J. Tucker; Lindsay E. Evans; Carl S. Rye et al.
Source: Self-asserted source
Birgit Wilding via Crossref Metadata Search

Demonstrating In-Cell Target Engagement using a Pirin Protein Degradation Probe (CCT367766)

Journal of Medicinal Chemistry
2017 | Journal article
DOI: 10.1021/acs.jmedchem.7b01406
Part of ISSN: 0022-2623
Contributors: Nicola E. A. Chessum; Swee Y. Sharp; John J Caldwell; A Elisa Pasqua; Birgit Wilding; Giampiero Colombano; Ian Collins; Bugra Ozer; Meirion Richards; Martin G. Rowlands et al.
Source: Self-asserted source
Birgit Wilding via Crossref Metadata Search
grade
Preferred source (of 2)‎

Newest Developments in the Preparation of Thieno[2,3-d]pyrimidines

Organic Preparations and Procedures International
2017-06-01 | Journal article
DOI: 10.1080/00304948.2017.1320513
Source: Self-asserted source
Birgit Wilding

Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen

Journal of Medicinal Chemistry
2017-01-12 | Journal article
DOI: 10.1021/acs.jmedchem.6b01055
Contributors: Matthew D. Cheeseman; Nicola E. A. Chessum; Carl S. Rye; A. Elisa Pasqua; Michael J. Tucker; Birgit Wilding; Lindsay E. Evans; Susan Lepri; Meirion Richards; Swee Y. Sharp et al.
Source: check_circle
Crossref

Kinetic analysis and probing with substrate analogues of the reaction pathway of the nitrile reductase QueF from Escherichia coli

Journal of Biological Chemistry
2016 | Journal article
DOI: 10.1074/jbc.M116.747014
Source: Self-asserted source
Birgit Wilding
grade
Preferred source (of 2)‎

ChemInform Abstract: A Practical Synthesis of 5-Functionalized Thieno[2,3-d]pyrimidines.

ChemInform
2015-10 | Journal article
DOI: 10.1002/chin.201544190
Part of ISSN: 0931-7597
Contributors: Birgit Wilding; Stefan Faschauner; Norbert Klempier
Source: Self-asserted source
Birgit Wilding via Crossref Metadata Search

The Nitrile Forming Enzyme 7-Cyano-7-Deazaguanine Synthase from Geobacillus kaustophilus: A Reverse Nitrilase?

ChemBioChem
2015-10-14 | Journal article
DOI: 10.1002/cbic.201500335
Source: Self-asserted source
Birgit Wilding

A convenient synthetic route to substituted pyrrolo[2,3-b]pyridines via a novel ethylene-bridged compound

Tetrahedron Letters
2015-10-07 | Journal article
DOI: 10.1016/j.tetlet.2015.10.031
Source: Self-asserted source
Birgit Wilding

An investigation of nitrile transforming enzymes in the chemo-enzymatic synthesis of the taxol sidechain

Organic & Biomolecular Chemistry
2015-06-17 | Journal article
DOI: 10.1039/C5OB01191D
Source: Self-asserted source
Birgit Wilding
grade
Preferred source (of 2)‎

A practical synthesis of 5-functionalized thieno[2,3-d]pyrimidines

Tetrahedron Letters
2015-05-27 | Journal article
DOI: 10.1016/j.tetlet.2015.05.104
Source: Self-asserted source
Birgit Wilding

Unconventional substrates for enzymatic reduction: carboxylates and nitriles

New Biotechnology
2014-07-10 | Conference abstract
DOI: 10.1016/j.nbt.2014.05.1616
Source: Self-asserted source
Birgit Wilding

Back Cover: Targeting the Substrate Binding Site ofE. coliNitrile Reductase QueF by Modeling, Substrate and Enzyme Engineering (Chem. Eur. J. 22/2013)

Chemistry - A European Journal
2013-05 | Journal article
DOI: 10.1002/chem.201390080
Part of ISSN: 0947-6539
Contributors: Birgit Wilding; Margit Winkler; Barbara Petschacher; Regina Kratzer; Sigrid Egger; Georg Steinkellner; Andrzej Lyskowski; Bernd Nidetzky; Karl Gruber; Norbert Klempier
Source: Self-asserted source
Birgit Wilding via Crossref Metadata Search

Targeting the Substrate Binding Site of E. coli Nitrile Reductase QueF by Modeling, Substrate and Enzyme Engineering

Chemistry - A European Journal
2013-04-27 | Journal article
DOI: 10.1002/chem.201300163
Source: Self-asserted source
Birgit Wilding

Nitrile Reductase from Geobacillus kaustophilus: A Potential Catalyst for a New Nitrile Biotransformation Reaction

Advanced Synthesis and Catalysis
2012-07-29 | Journal article
DOI: 10.1002/adsc.201200109
Source: Self-asserted source
Birgit Wilding
How many people are using ORCID?